Ezrin expression combined with MSI status in prognostication of stage II colorectal cancer
| Autor: | Olli Carpén, Taina Korpela, Khadija Slik, Eija Korkeila, Samu Kurki, Jari Sundström |
|---|---|
| Přispěvatelé: | Medicum, Department of Pathology, Research Programs Unit, Genome-Scale Biology (GSB) Research Program, Precision Cancer Pathology |
| Jazyk: | angličtina |
| Rok vydání: | 2017 |
| Předmět: |
0301 basic medicine
Oncology Male TUMOR MICROSATELLITE-INSTABILITY PROGNOSIS Colorectal cancer Cancer Treatment lcsh:Medicine Negative Staining 0302 clinical medicine Ezrin ADJUVANT CHEMOTHERAPY Medicine and Health Sciences ta319 lcsh:Science BRAF MUTATION STATUS Staining Multidisciplinary Tissue microarray Paraffin Embedding Pharmaceutics COLON-CANCER ASSOCIATION 3. Good health Surgical Oncology 030220 oncology & carcinogenesis SURVIVAL Female Anatomy Colorectal Neoplasms Research Article Clinical Oncology Proto-Oncogene Proteins B-raf medicine.medical_specialty Histology 3122 Cancers Surgical and Invasive Medical Procedures MLH1 Research and Analysis Methods Lymphatic System 03 medical and health sciences Cancer Chemotherapy Drug Therapy Internal medicine medicine TUMORIGENESIS Chemotherapy Humans Immunohistochemistry Techniques Survival analysis Radical Surgery Aged Colorectal Cancer MISMATCH-REPAIR STATUS business.industry lcsh:R Cancer Cancers and Neoplasms Biology and Life Sciences medicine.disease ta3122 Survival Analysis Histochemistry and Cytochemistry Techniques Cytoskeletal Proteins 030104 developmental biology MSH2 Specimen Preparation and Treatment Tissue Array Analysis CELLS Cancer research Immunologic Techniques lcsh:Q Lymph Nodes Clinical Medicine business V600E Microsatellite Repeats |
| Zdroj: | PLoS ONE, Vol 12, Iss 9, p e0185436 (2017) PLoS ONE |
| Popis: | Currently used factors predicting disease recurrence in stage II colorectal cancer patients are not optimal for risk stratification. Thus, new biomarkers are needed. In this study the applicability of ezrin protein expression together with MSI status and BRAF mutation status were tested in predicting disease outcome in stage II colorectal cancer. The study population consisted of 173 stage II colorectal cancer patients. Paraffin-embedded cancer tissue material from surgical specimens was used to construct tissue microarrays (TMAs) with next-generation technique. The TMA-slides were subjected to following immunohistochemical stainings: MLH1, MSH2, MSH6, PMS2, ezrin and anti-BRAF V600E antibody. The staining results were correlated with clinicopathological variables and survival. In categorical analysis, high ezrin protein expression correlated with poor disease-specific survival (p = 0.038). In univariate analysis patients having microsatellite instabile / low ezrin expression tumors had a significantly longer disease-specific survival than patients having microsatellite stable / high ezrin expression tumors (p = 0.007). In multivariate survival analysis, the presence of BRAF mutation was associated to poor overall survival (p = 0.028, HR 3.29, 95% CI1.14-9.54). High ezrin protein expression in patients with microsatellite stable tumors was linked to poor disease-specific survival (p = 0.01, HR 5.68, 95% CI 1.53-21.12). Ezrin protein expression is a promising biomarker in estimating the outcome of stage II colorectal cancer patients. When combined with microsatellite status its ability in predicting disease outcome is further improved. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|